These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23443994)

  • 1. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
    Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
    Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entacapone and prostate cancer risk in patients with Parkinson's disease.
    Korhonen P; Kuoppamäki M; Prami T; Hoti F; Christopher S; Ellmén J; Aho V; Vahteristo M; Pukkala E; Haukka J
    Mov Disord; 2015 Apr; 30(5):724-8. PubMed ID: 25639262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of phase III with entacapone in Parkinson's disease.
    Kuoppamäki M; Vahteristo M; Ellmén J; Kieburtz K
    Acta Neurol Scand; 2014 Oct; 130(4):239-47. PubMed ID: 25186800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
    Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
    J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
    Kupsch A; Trottenberg T; Bremen D
    Curr Med Res Opin; 2004 Jan; 20(1):115-20. PubMed ID: 14741081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.